The Cognitive Ageing Nutrition and Neurogenesis (CANN) Trial

Inclusion Criteria: * Male and female, aged ≥ 55 years * Mild cognitive impairment (MCI) or subjective memory impairment (SMI) with no indication of clinical dementia or depression * Willing and able to provide written informed consent. * Understands and is willing and able to comply with all study procedures. * Fluent in written and spoken English. * In good general health including blood biochemical, haematological and urinalysis within the normal range at screening (as judged by the clinical advisor) * Normal, or corrected to normal vision and hearing * Right handed, for MRI * Stable use of any prescribed medication for at least four weeks Exclusion Criteria: * Diagnosis of Alzheimer's disease (AD) or other form of dementia or significant neurological disorder * Parent or sibling who developed premature dementia \<60y (suggestive of a familial monogenic form of cognitive decline) * Past history or MRI evidence of brain damage including significant trauma, stroke, learning difficulties or serious neurological disorder, including loss of consciousness \> 24 hours * History of alcohol or drug dependency within the last 2 years * Other clinically diagnosed psychiatric disorder likely to affect the cognitive measures (as judged by clinical adviser) * Existing diagnosed gastrointestinal disorders likely to impact on absorption of flavonoids and fatty acids (as judged by clinical adviser) * Major cardiovascular event, e.g. myocardial infarction or stroke, in the last 12 months * Carotid stents or severe stenosis * Known allergy to fish or any other component in the intervention supplements * Existing medical conditions likely to affect the study measures (as judged by clinical adviser) * Uncontrolled hypertension (Systolic Blood Pressure (SBP) \>140mmHg, Diastolic Blood Pressure (DBP) \>90mmHg) * BMI \>40kg/m2